GLP-1 News & Updates
Daily summaries of the most important GLP-1 stories — FDA decisions, clinical research, telehealth updates, and insurance coverage changes.
Today — Saturday, April 4, 2026
4 articlesNovo Nordisk Fires Back: Claims Wegovy Pill Outperforms Lilly's Foundayo in Weight Loss
TLDR: Novo Nordisk responded to Foundayo's approval by releasing cross-trial data showing oral Wegovy achieved 16.6% average weight loss versus Foundayo's 12.4%. However, analysts note the comparison is imperfect since the drugs were not tested head-to-head, and Foundayo's advantage of no food or water restrictions may drive stronger patient adherence.
Read full story →Trump's Medicare GLP-1 Plan Would Cost Insurers Billions, Bloomberg Analysis Finds
TLDR: A Bloomberg analysis estimates that the administration's plan to cover GLP-1 weight loss drugs under Medicare Part D would cost insurers billions annually. The CMS BALANCE Model launching in July 2026 at $50 per month per beneficiary is expected to drive massive enrollment, raising questions about long-term program sustainability.
Read full story →Foundayo Prescriptions Now Open, First Shipments Begin April 6
TLDR: Eli Lilly began accepting prescriptions for Foundayo through LillyDirect, with shipping starting April 6 and broad retail pharmacy availability to follow. Eligible patients with commercial insurance can pay as little as $25 per month with a savings card, while self-pay starts at $149 per month for the lowest dose.
Read full story →FDA Warns Novo Nordisk Over Misleading Ozempic Television Advertisement
TLDR: The FDA issued a warning letter to Novo Nordisk stating that a recent Ozempic TV ad contained false or misleading claims suggesting superiority over other GLP-1 diabetes drugs. The agency cited violations of the Federal Food, Drug, and Cosmetic Act for overstating efficacy without adequate risk disclosure.
Read full story →Yesterday — Friday, April 3, 2026
4 articlesEli Lilly's Foundayo Pill Approved by FDA — No Food or Water Restrictions Required
TLDR: The FDA approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for weight loss, which can be taken any time of day without food or water restrictions. It is the first new molecular entity approved under the National Priority Voucher program, with the review completed in just 50 days. Available starting at $149/month out of pocket.
Read full story →Novo Nordisk Says Oral Wegovy Now Broadly Available Across America
TLDR: Novo Nordisk announced that the oral version of Wegovy, the first FDA-approved GLP-1 pill for weight loss, is now broadly available at pharmacies nationwide. The pill competes directly with Lilly's newly approved Foundayo, though it requires morning dosing on an empty stomach.
Read full story →GLP-1 Drugs Reshaping U.S. Retail Spending Patterns, New Analysis Finds
TLDR: An analysis of nearly 96,000 GLP-1 consumer conversations reveals how medication adoption is restructuring U.S. retail demand, with shifts in food, fitness, and apparel purchasing patterns that retailers are failing to anticipate.
Read full story →Commercial Insurance Coverage for GLP-1 Weight Loss Drugs Shrinks in 2026
TLDR: The number of people without commercial insurance coverage for Wegovy jumped 42% compared to 2025, leaving over 41 million uninsured for the drug. Over 88% of those with coverage still face prior authorization hurdles, even as Medicare prepares to expand access through the BALANCE Model starting mid-2026.
Read full story →Wednesday — Wednesday, April 1, 2026
4 articlesFDA Decision on Eli Lilly Oral GLP-1 Pill Orforglipron Expected April 10
TLDR: The FDA is expected to issue its approval decision on orforglipron, Eli Lilly's once-daily oral GLP-1, by April 10. Phase 3 trials showed the drug achieved up to 12.4% weight loss and outperformed oral semaglutide for blood sugar control. If approved, it would become the second oral GLP-1 for weight management.
Read full story →Wegovy Pill Pricing Shifts: 4 mg Dose Rises to $199 After April 15
TLDR: Novo Nordisk's oral Wegovy is now available at over 70,000 U.S. pharmacies. The introductory $149 monthly price for the 4 mg dose expires April 15 and will increase to $199. The starter 1.5 mg dose remains at $149, while the highest doses will cost $299 per month.
Read full story →Medicare GLP-1 Bridge Program to Launch July 2026 at $50 per Month
TLDR: CMS confirmed its Medicare GLP-1 Bridge demonstration will begin in July 2026, offering eligible beneficiaries GLP-1 medications for $50 per month. The program serves as a precursor to the full BALANCE Model launching in Medicare Part D in January 2027 and Medicaid as early as May 2026.
Read full story →FDA Tightens Enforcement on Compounded Semaglutide as Shortage Officially Ends
TLDR: With injectable semaglutide no longer in shortage, the FDA has ended its enforcement discretion for compounders. Compounded semaglutide is now restricted to rare patient-specific cases with documented medical necessity, and the agency has issued warnings about dangerous impurities found in some compounded products.
Read full story →Tuesday — Tuesday, March 31, 2026
4 articlesBioNxt Advances Semaglutide Oral Dissolving Film as Next-Gen GLP-1 Delivery
TLDR: BioNxt Solutions announced progress on its semaglutide oral dissolving film platform, a sublingual delivery system that could offer faster absorption and easier dosing than current GLP-1 pills. The company is also evaluating expansion to tirzepatide and liraglutide compounds.
Read full story →GLP-1 Patent Cliff Accelerates as Brazil Opens Door to Generic Semaglutide
TLDR: Brazil denied Novo Nordisk's request to extend semaglutide patent protection, opening a major market to generic competition. Combined with patent expirations in China and India, the global GLP-1 generic landscape is shifting rapidly in 2026.
Read full story →CMS Launches BALANCE Model to Expand Medicare and Medicaid GLP-1 Coverage
TLDR: The Centers for Medicare and Medicaid Services launched the BALANCE model to expand GLP-1 access for federal program beneficiaries. Medicare Part D enrollees can expect coverage by July 2026 through a bridge program, with Medicaid BALANCE coverage starting as early as May 2026.
Read full story →Experts Say GLP-1 Drugs Could Transform Global Health But Affordability Remains Critical Barrier
TLDR: Health experts argue that GLP-1 medications have transformative potential for global public health but remain inaccessible to most of the world due to high costs. The call for affordable access is intensifying as patent cliffs approach and generic manufacturers prepare to enter markets worldwide.
Read full story →Sunday — Sunday, March 29, 2026
4 articlesEli Lilly Retatrutide Achieves Up to 17% Weight Loss in Phase 3 Type 2 Diabetes Trial
TLDR: Phase 3 TRANSCEND-T2D-1 results show retatrutide, a triple-hormone agonist, delivered up to 2.0% A1C reduction and 16.8% body weight loss at 40 weeks in adults with type 2 diabetes. The data positions retatrutide as a potential next-generation treatment beyond current GLP-1 options.
Read full story →Pfizer Monthly-Dose GLP-1 Injectable Shows Robust Weight Loss in Phase 2b Trial
TLDR: Pfizer reported that its ultra-long-acting injectable GLP-1 receptor agonist achieved continued weight loss with just once-monthly dosing in a Phase 2b study. The monthly schedule could offer a major convenience advantage over current weekly injections.
Read full story →Oral Wegovy Reaches 400K Users as Lilly Orforglipron Nears FDA Decision
TLDR: Novo Nordisk oral semaglutide pill has been adopted by roughly 400,000 Americans just 10 weeks after FDA approval, priced at $149 per month for out-of-pocket patients. Meanwhile, Eli Lilly expects FDA approval of its competing oral GLP-1 orforglipron by the end of June.
Read full story →FDA Issues 30 Warning Letters to Compounded GLP-1 Telehealth Companies
TLDR: The FDA escalated enforcement against compounded GLP-1 drugs with 30 new warning letters targeting telehealth companies making false or misleading claims. Novo Nordisk has also sued Hims & Hers over patent infringement related to compounded semaglutide products.
Read full story →Saturday — Saturday, March 28, 2026
5 articlesWhat GLP-1 Drugs Actually Do to Your Body, From Head to Toe
TLDR: Comprehensive deep-dive into how GLP-1 medications affect nearly every organ system — from the brain and heart to the gut and kidneys. The article highlights emerging evidence that benefits extend well beyond weight loss, including cardiovascular protection and reduced inflammation.
Read full story →Ozempic Linked to Major Drops in Depression, Anxiety, and Addiction Risk
TLDR: A large-scale study found semaglutide users experienced 44% lower depression risk, 38% fewer anxiety disorders, and 47% fewer substance-use-related hospitalizations during treatment. Researchers say the mental health benefits may be independent of weight loss itself.
Read full story →FDA Sends 30 Warning Letters to Telehealth Companies Over Compounded GLP-1 Ads
TLDR: The FDA escalated its crackdown on compounded GLP-1 marketing, sending 30 new warning letters to telehealth companies making misleading claims about compounded semaglutide and tirzepatide. The agency threatened legal action without further notice for non-compliance.
Read full story →Expert Calls Retreat From GLP-1 Coverage 'Bordering on Unethical'
TLDR: As Massachusetts insurers drop GLP-1 coverage for weight loss in 2026, clinicians warn that pulling access to effective obesity treatments puts patient health at risk. One expert called the decision bordering on unethical given the strong clinical evidence.
Read full story →India Launches Cheap Weight-Loss Drugs as Novo Nordisk Bets Brands Will Stay on Top
TLDR: Novo Nordisk launched Wegovy and Ozempic in India under new brand names through local partnerships, while Eli Lilly already sells Mounjaro and Zepbound at significantly lower prices. The Indian market could reshape global GLP-1 pricing expectations.
Read full story →Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.